Overview
Faculty
Agenda
Registration
View Archive

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Genmab US Inc., Janssen Scientific Affairs, LLC, Karyopharm Therapeutics, and Pharmacyclics LLC, an AbbVie Company.

New Targets, New Data, New Guidelines: Assessing Treatment Options to Personalize Care in B-Cell Lymphomas

New Targets, New Data, New Guidelines: Assessing Treatment Options to Personalize Care in B-Cell Lymphomas


Friday, December 4, 2020

Live, Interactive Virtual Webcast!

11:00 AM – 1:15 PM PST

Overview

Approximately 77,240 new cases of non-Hodgkin lymphoma (NHL) and 19,940 NHL-related deaths are expected in the United States in 2020. The 3 most common subtypes of NHL are diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). In recent years, increased understanding of the immune microenvironment and mechanisms of evasion of immune surveillance in hematological malignancies have led to the development of novel treatment strategies in the second-line and maintenance settings in patients with these common subtypes of NHL. Recent developments in these therapeutic areas include many practice-changing findings and positive results with several medications in phase III development.

New Targets, New Data, New Guidelines: Assessing Treatment Options to Personalize Care in B-Cell Lymphomas is a CME-certified live webcast to be held Friday, December 4, 2020. In this educational program, renowned experts in NHL will review the role of biomarkers in prognostication and clinical decision-making, as well as current and emerging therapies for the treatment of DLBCL, FL, and MCL in the second-line and maintenance settings. The experts will share clinical insight in applying the evidence from recent clinical trials and best practices for the management of treatment-related adverse events.

Benefits of Attending

  • Examine the role of tumor biomarkers in the management of patients with B-cell lymphomas
  • Review recent data regarding the efficacy and safety of new and emerging agents for B-cell lymphomas
  • Discover expert insights on how to apply emerging evidence and recent approvals to your practice
  • Learn best practices to mitigate and manage adverse events associated with therapies for B-cell lymphomas
  • Discuss investigational approaches for B-cell lymphomas and clinical trial opportunities for your patients

Acknowledgment of Commercial Support

This activity is supported by educational grants from Genmab US Inc., Janssen Scientific Affairs, LLC, Karyopharm Therapeutics, and Pharmacyclics LLC, an AbbVie Company.

Target Audience

This educational activity is directed toward medical oncologists, hematologists, and other oncology health care professionals interested in the latest advances in the treatment of patients with non-Hodgkin lymphoma. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with non-Hodgkin lymphoma are also invited to attend.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe tumor biomarkers across NHLs in the context of NHL pathophysiology to understand the relevance of these data in determining patient prognosis and selecting appropriate therapy for patients with DLBCL, FL, and MCL
  • Integrate available treatment strategies, including chemotherapy-free treatment strategies across NHLs, to better understand the efficacy and safety of these agents in patients with DLBCL, FL, and MCL
  • Evaluate approaches to mitigate, monitor, and manage adverse events associated with therapeutic regimens used in the treatment of patients DLBCL, FL, and MCL
  • Assess clinical trials of novel agents and therapeutic combinations for patients with DLBCL, FL, and MCL

Hot Topics

  • Importance of tumor biomarker evaluation for clinical management of patients with NHL
  • Advancements in therapeutic options for the management of DLBCL, FL, and MCL
  • Identification and management of treatment-related adverse events

Program Chair

Brad S. Kahl, MD
Brad S. Kahl, MD
Professor of Medicine
Washington University School of Medicine
St. Louis, MO

Registration

2 Ways to Register
  1. Online: click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
 
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

Meeting information is accurate at the time of posting.



Register

You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information


Registration Information


Professional Information


Specialties*

Submit
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
31
Filter By